Do not count Eli Lilly's oral medication for obesity and diabetes yet, according to Jim Cramer de CNBC. That was his conclusion after the last study that involved Orforgripron de Lilly, the experimental pill that has been subject to Wall Street debate since the weight loss data published in early August occurred below the expectations of investors. The action fell by 14% in a single day, since investors feared that their expectations for sales of orforglipron in the coming years were too optimistic. Lilly's shares have fought since that fall, even before the new data on Wednesday showed that Orforgripron surpassed Oral Navo Nordisk itself by Novo Nordisk by reducing blood sugar levels for patients with type 2 diabetes in a 52-week study. The Blockbuster GLP-1 market is currently dominated by weekly injectables by Lilly and Novo Nordisk. Speaking in “Squawk on the street” by CNBC, Cramer suggested that the results of Wednesday reinforce the attractiveness of Orforglipron, which is taken once a day. “Persistence is the enemy of these at this time. People abandon … due to injectables. They are afraid in this country,” said Cramer, whose charitable confidence, the portfolio used by the CNBC Investing Club, has had Lilly actions for a long time. These drugs mimic an intestinal hormone, known as LPG-1, which helps them regulate blood sugar and effectively suppress appetite, which leads to weight loss. That makes them useful to treat both type 2 diabetes and obesity. The opportunity for the treatment of obesity, in particular, has excited Wall Street, leading to analysts' forecasts that the market could be worth more than $ 100 billion by 2030. The injectable versions of the LPG-1 have faced supply limitations given the complexities of manufacturing them. They also require cold storage. None of those obstacles to distribution applies to Lilly's pill. “A pill is something excellent because you don't have to keep it in a refrigerator; the refrigerator is messy. The fact that they could, perhaps, have a pill that will do it even more will do so to make this more a drug for life,” Cramer said. That is what they have been looking for. “
